Why So Few?

Some clinical cancer trials don't attract the wanted number of participants. And there are a number of reasons why, such as competing trials, conditions with low annual incidence, and whether they focus on older treatments rather than newer ones, according to researchers from the University of Washington and the Fred Hutchinson Cancer Research Center.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.